Yarrow Bioscience Q2 FY26 net loss narrows to $6.51 million; R&D expenses rise to $4.94 million

• Yarrow posted a net loss of $6.5 million in Q2 2026, with R&D expense of $4.9 million and G&A expense of $1.8 million.
• Cash and cash equivalents were $18.7 million at June 30, 2026; expects operations funded into 2028 including $100 million received in July.
• Initiated a Phase 2a/2b trial of YB-101 in Graves' disease; Phase 2a topline data expected in H2 2027.
• FDA granted Fast Track designation for YB-101 in Graves' disease; Phase 2b trial planned to start in H1 2028.
• GenSci continues a Phase 1 multiple-ascending-dose study of YB-101 in thyroid eye disease in China; data expected in H2 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Yarrow Bioscience Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260812665930) on August 13, 2026, and is solely responsible for the information contained therein.